NCT01951170View on ClinicalTrials.gov

An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Tocilizumab

162 milligrams (mg) tocilizumab was administered subcutaneously once weekly for 24 weeks

Trial Locations (10)

2050

Camperdown

2217

Kogarah

2450

Coffs Harbour

3079

Ivanhoe

3145

Malvern East

3220

Geelong

3842

Morwell

4215

Southport

5000

Adelaide

7000

Hobart

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01951170 - An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter